About Reata Pharmaceuticals (NASDAQ:RETA)
Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases. The Company's lead product candidates include bardoxolone methyl, which is being studied in Phase III trial for the treatment of pulmonary arterial hypertension (PAH), associated with connective tissue disease (CTD-PAH), as well as a Phase II trial for the treatment of pulmonary hypertension due to interstitial lung disease (PH-ILD), and PAH, each of which are subsets of pulmonary hypertension (PH), Omaveloxolone, which is in Phase II clinical development for the treatment of multiple diseases, including Friedreich's ataxia, mitochondrial myopathies and metastatic melanoma.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RETA
CUSIPN/A
Phone972-865-2219
Debt
Debt-to-Equity Ratio-0.13%
Current Ratio2.80%
Quick Ratio2.80%
Price-To-Earnings
Trailing P/E Ratio-13.16
Forward P/E Ratio-10.27
P/E GrowthN/A
Sales & Book Value
Annual Sales$48.06 million
Price / Sales14.25
Cash FlowN/A
Price / CashN/A
Book Value($5.62) per share
Price / Book-4.66
Profitability
EPS (Most Recent Fiscal Year)($1.99)
Net Income$-47,670,000.00
Net Margins-99.19%
Return on EquityN/A
Return on Assets-41.89%
Miscellaneous
Employees93
Outstanding Shares26,150,000
Reata Pharmaceuticals (NASDAQ:RETA) Frequently Asked Questions
What is Reata Pharmaceuticals' stock symbol?
Reata Pharmaceuticals trades on the NASDAQ under the ticker symbol "RETA."
How were Reata Pharmaceuticals' earnings last quarter?
Reata Pharmaceuticals (NASDAQ:RETA) posted its quarterly earnings results on Friday, March, 2nd. The company reported ($0.64) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.08. The company had revenue of $9.96 million for the quarter, compared to analyst estimates of $11.18 million. View Reata Pharmaceuticals' Earnings History.
What price target have analysts set for RETA?
8 brokers have issued 12-month price objectives for Reata Pharmaceuticals' shares. Their forecasts range from $43.00 to $78.00. On average, they expect Reata Pharmaceuticals' share price to reach $54.7143 in the next year. View Analyst Ratings for Reata Pharmaceuticals.
What are Wall Street analysts saying about Reata Pharmaceuticals stock?
Here are some recent quotes from research analysts about Reata Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Reata Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is engaged in identifying, developing and commercializing product candidates which modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress and inflammation to address the unmet medical needs of serious or life-threatening diseases. Reata Pharmaceuticals, Inc. is based in Irving, United States. " (3/7/2018)
- 2. Cowen Inc analysts commented, "RETA reported 3Q17 financials yesterday, noting that the three major programs." (11/14/2017)
Who are some of Reata Pharmaceuticals' key competitors?
Some companies that are related to Reata Pharmaceuticals include Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND), Evotec A.G. (EVTCY), Ironwood Pharmaceuticals (IRWD), Acadia Pharmaceuticals (ACAD), Clovis Oncology (CLVS), Supernus Pharmaceuticals (SUPN), Puma Biotechnology (PBYI), Portola Pharmaceuticals (PTLA), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT), Heron Therapeutics (HRTX), Medicines (MDCO) and AnaptysBio (ANAB).
Who are Reata Pharmaceuticals' key executives?
Reata Pharmaceuticals' management team includes the folowing people:
- J. Warren Huff, Chairman of the Board, President, Chief Executive Officer (Age 63)
- Jason Dauglas Wilson CPA, Chief Financial Officer and Vice President, Strategy (Age 47)
- Colin John Meyer MD, PhD, Chief Medical Officer and Vice President, Product Development (Age 38)
- Keith Wayne Ward, Vice President, Chief Development Officer (Age 47)
- Michael D. Wortley, Vice President, Chief Legal Officer (Age 69)
- Dawn C. Bir, Chief Commercial Officer (Age 46)
- William D. McClellan Jr. CPA, Director (Age 57)
- James Edward Bass, Independent Director (Age 58)
- R. Kent McGaughy Jr., Independent Director (Age 45)
- Jack B. Nielsen, Independent Director (Age 53)
When did Reata Pharmaceuticals IPO?
(RETA) raised $60 million in an IPO on Thursday, May 26th 2016. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Citigroup, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO.
Has Reata Pharmaceuticals been receiving favorable news coverage?
News coverage about RETA stock has been trending positive on Friday, Accern reports. Accern identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Reata Pharmaceuticals earned a media sentiment score of 0.26 on Accern's scale. They also assigned media coverage about the company an impact score of 46.62 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next several days.
How do I buy shares of Reata Pharmaceuticals?
Shares of RETA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Reata Pharmaceuticals' stock price today?
One share of RETA stock can currently be purchased for approximately $26.19.
How big of a company is Reata Pharmaceuticals?
Reata Pharmaceuticals has a market capitalization of $656.99 million and generates $48.06 million in revenue each year. The company earns $-47,670,000.00 in net income (profit) each year or ($1.99) on an earnings per share basis. Reata Pharmaceuticals employs 93 workers across the globe.
How can I contact Reata Pharmaceuticals?
Reata Pharmaceuticals' mailing address is 2801 GATEWAY DRIVE SUITE 150, IRVING TX, 75063. The company can be reached via phone at 972-865-2219 or via email at [email protected]
MarketBeat Community Rating for Reata Pharmaceuticals (RETA)
MarketBeat's community ratings are surveys of what our community members think about Reata Pharmaceuticals and other stocks. Vote "Outperform" if you believe RETA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RETA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Reata Pharmaceuticals (NASDAQ:RETA) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Reata Pharmaceuticals in the last 12 months. Their average twelve-month price target is $54.7143, suggesting that the stock has a possible upside of 108.91%. The high price target for RETA is $78.00 and the low price target for RETA is $43.00. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.88 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $54.7143 | $54.7143 | $54.7143 | $54.7143 |
| Price Target Upside: | 108.91% upside | 116.95% upside | 116.95% upside | 67.78% upside |
Reata Pharmaceuticals (NASDAQ:RETA) Consensus Price Target History
Reata Pharmaceuticals (NASDAQ:RETA) Analyst Ratings History
Show:
(Data available from 4/27/2016 forward)
Reata Pharmaceuticals (NASDAQ:RETA) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Reata Pharmaceuticals (NASDAQ RETA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 44.00%
Institutional Ownership Percentage: 49.26%
Reata Pharmaceuticals (NASDAQ RETA) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/29/2017 | James W Traweek Jr | Major Shareholder | Buy | 17,000 | $28.47 | $483,990.00 | 35 |  |
| 12/29/2017 | R Kent Mcgaughy Jr | Director | Buy | 17,000 | $28.47 | $483,990.00 | 113 | |
| 12/28/2017 | James W Traweek Jr | Major Shareholder | Buy | 27,200 | $25.93 | $705,296.00 | 35 | |
| 12/27/2017 | R Kent Mcgaughy Jr | Director | Buy | 15,000 | $25.83 | $387,450.00 | 25,004 | |
| 12/26/2017 | James W Traweek Jr | Major Shareholder | Buy | 12,000 | $26.06 | $312,720.00 | 35 | |
| 12/14/2017 | Cpmg Inc | Director | Buy | 200,000 | $24.79 | $4,958,000.00 | 113 | |
| 12/13/2017 | James W Traweek Jr | Major Shareholder | Buy | 121,725 | $24.88 | $3,028,518.00 | 35 | |
| 11/15/2017 | James Edward Bass | Director | Buy | 3,888 | $24.02 | $93,389.76 | 52,089 | |
| 8/1/2017 | James Edward Bass | Director | Buy | 8,064 | $31.00 | $249,984.00 | 67,411 | |
| 6/14/2017 | A/S Novo | Major Shareholder | Sell | 61,000 | $25.11 | $1,531,710.00 | 642,405 | |
| 6/13/2017 | A/S Novo | Major Shareholder | Sell | 11,389 | $25.47 | $290,077.83 | 642,405 | |
| 6/12/2017 | A/S Novo | Major Shareholder | Sell | 222,503 | $25.71 | $5,720,552.13 | 746,297 | |
| 6/7/2017 | A/S Novo | Major Shareholder | Sell | 89,497 | $28.24 | $2,527,395.28 | 942,467 | |
| 6/6/2017 | A/S Novo | Major Shareholder | Sell | 64,170 | $28.09 | $1,802,535.30 | 942,467 | |
| 6/5/2017 | A/S Novo | Major Shareholder | Sell | 23,327 | $28.67 | $668,785.09 | 942,467 | |
| 3/28/2017 | Abbvie Inc. | Major Shareholder | Sell | 450,000 | $22.50 | $10,125,000.00 | 1,190,473 | |
| 12/30/2016 | Cpmg Inc | Director | Buy | 9,392 | $21.72 | $203,994.24 | 113 | |
| 12/16/2016 | Cpmg Inc | Director | Buy | 164,753 | $22.99 | $3,787,671.47 | 113 | |
| 12/15/2016 | James W Traweek Jr | Major Shareholder | Buy | 8,889 | $21.57 | $191,735.73 | 35 | |
| 12/14/2016 | James Edward Bass | Director | Buy | 5,000 | $21.76 | $108,800.00 | 30,585 | |
| 8/22/2016 | Jack Nielsen | Director | Buy | 1,780 | $17.00 | $30,260.00 | 1,780 | |
| 8/18/2016 | R Kent Mcgaughy Jr | Director | Buy | 308,220 | $17.08 | $5,264,397.60 | 25,004 | |
| 8/16/2016 | Colin John Meyer | Insider | Buy | 7,000 | $16.26 | $113,820.00 | 27,172 | |
| 6/30/2016 | James W Traweek Jr | Major Shareholder | Buy | 164,600 | $19.78 | $3,255,788.00 | 35 | |
| 6/27/2016 | Cpmg Inc | Director | Buy | 73,403 | $19.26 | $1,413,741.78 | 113 | |
| 6/7/2016 | R Kent Mcgaughy Jr | Director | Buy | 24,220 | $17.57 | $425,545.40 | 25,004 | |
| 6/1/2016 | A/S Novo | Major Shareholder | Buy | 750,000 | $11.00 | $8,250,000.00 | 750,000 | |
| 6/1/2016 | James Warren Huff | Insider | Buy | 114,000 | $11.00 | $1,254,000.00 | 62,657 | |
| 6/1/2016 | R Kent Mcgaughy Jr | Director | Buy | 251,553 | $12.70 | $3,194,723.10 | 25,004 | |
(Data available from 1/1/2013 forward)
Reata Pharmaceuticals (NASDAQ RETA) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich's ...
globenewswire.com - April 26 at 10:04 AM |
 | BRIEF-Reata Pharmaceuticals Announces New Preclinical Data Of Omaveloxolone
www.reuters.com - April 26 at 10:04 AM |
 | $10.21 Million in Sales Expected for Reata Pharmaceuticals (RETA) This Quarter
www.americanbankingnews.com - April 26 at 4:32 AM |
 | Reata Announces New Preclinical Data Demonstrating the Potential of Omaveloxolone in the Treatment of Friedreich’s Ataxia and Other Severe Neurological Diseases
finance.yahoo.com - April 25 at 10:39 AM |
| -$0.66 Earnings Per Share Expected for Reata Pharmaceuticals (RETA) This Quarter
www.americanbankingnews.com - April 24 at 8:08 AM |
| Reata Pharmaceuticals (RETA) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - April 20 at 11:55 AM |
| Citigroup Reaffirms "Buy" Rating for Reata Pharmaceuticals (RETA)
www.americanbankingnews.com - April 16 at 1:54 PM |
 | Reata Pharma's bardoxolone shows treatment effect in mid-stage portion of Alport syndrome study
seekingalpha.com - April 12 at 11:08 AM |
| Reata Provides Update on the Phase 2 Portion of the CARDINAL Study of Bardoxolone Methyl in Patients With Alport Syndrome
finance.yahoo.com - April 12 at 11:08 AM |
 | 8 Stocks Moving In Wednesday's After-Hours Session
feeds.benzinga.com - April 11 at 7:10 PM |
| Achillion, Omeros, Ra Rx, Reata, ChemoCentryx, And Others In The IgA Nephropathy Space
seekingalpha.com - April 9 at 3:56 PM |
| Cowen Reiterates "Hold" Rating for Reata Pharmaceuticals (RETA)
www.americanbankingnews.com - April 9 at 6:02 AM |
| Zacks: Analysts Expect Reata Pharmaceuticals Inc (RETA) Will Post Quarterly Sales of $10.21 Million
www.americanbankingnews.com - April 9 at 3:32 AM |
| Reata Pharmaceuticals (RETA) Upgraded by ValuEngine to Hold
www.americanbankingnews.com - April 8 at 7:34 PM |
| Reata Pharmaceuticals Inc (RETA) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 8 at 3:36 AM |
| Reata Pharmaceuticals (RETA) Downgraded by ValuEngine
www.americanbankingnews.com - April 7 at 8:50 PM |
| -$0.66 EPS Expected for Reata Pharmaceuticals Inc (RETA) This Quarter
www.americanbankingnews.com - April 7 at 9:53 AM |
| Reata Pharmaceuticals (RETA) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 5 at 11:20 PM |
| Reata to Present Preclinical Data on RTA 1701, a Novel RORγt Inverse Agonist, at Upcoming Immunology Conference
finance.yahoo.com - April 3 at 10:32 AM |
| Reata Pharmaceuticals (RETA) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - April 1 at 12:08 AM |
| Reata licensee Kyowa Hakko Kirin nabs accelerated review status in Japan for bardoxolone in DKD
seekingalpha.com - March 30 at 10:20 AM |
| Reata Announces That Kyowa Hakko Kirin Received SAKIGAKE Priority Review Designation for Bardoxolone Methyl in Japan
finance.yahoo.com - March 30 at 10:20 AM |
| Zacks Investment Research Downgrades Reata Pharmaceuticals (RETA) to Sell
www.americanbankingnews.com - March 26 at 10:58 AM |
| Reata Pharmaceuticals (RETA) Downgraded by BidaskClub
www.americanbankingnews.com - March 26 at 9:55 AM |
| U.S. Biotech/Pharma Sector Daily Observations Letter: March 22, 2018
seekingalpha.com - March 24 at 4:23 PM |
| Reata Pharmaceuticals Inc (RETA) Expected to Announce Quarterly Sales of $10.21 Million
www.americanbankingnews.com - March 23 at 4:56 AM |
 | Reata Pharma (RETA) Reports Positive Top-Line Data for Treatment of PH-ILD with Bardoxolone Methyl From the ... - StreetInsider.com
www.streetinsider.com - March 22 at 10:00 AM |
| Reata Announces Positive Top-Line Data for Treatment of PH-ILD With Bardoxolone Methyl From the Phase 2 Lariat Trial
finance.yahoo.com - March 22 at 10:00 AM |
| Reata Pharmaceuticals Inc (RETA) Expected to Announce Earnings of -$0.66 Per Share
www.americanbankingnews.com - March 21 at 12:36 PM |
| Reata Selected to Present Early-Stage Programs at the BIO Asia International Conference - GlobeNewswire (press release)
globenewswire.com - March 18 at 3:56 PM |
| Reata Selected to Present Early-Stage Programs at the BIO Asia International Conference
finance.yahoo.com - March 17 at 11:08 AM |
| Reata Pharmaceuticals Inc (RETA) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - March 14 at 3:42 AM |
| Reata Pharmaceuticals Inc (RETA) to Post Q1 2018 Earnings of ($0.55) Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - March 8 at 6:30 AM |
| Prosight Management LP Purchases Shares of 172,897 Reata Pharmaceuticals Inc (RETA)
www.americanbankingnews.com - March 5 at 3:30 PM |
| Reata Pharmaceuticals (RETA) Announces Quarterly Earnings Results, Misses Expectations By $0.08 EPS
www.americanbankingnews.com - March 3 at 10:38 AM |
| Reata Pharma (RETA) Reports Top-Line Data from Dose-Escalation ... - StreetInsider.com
www.streetinsider.com - March 2 at 3:53 PM |
| Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full ... - GlobeNewswire (press release)
globenewswire.com - March 2 at 3:53 PM |
| Reata Pharma (RETA) Reports Top-Line Data from Dose-Escalation Cohorts of Phase 2 Moto Trial of Omaveloxolone
www.streetinsider.com - March 2 at 10:26 AM |
| Reata Announces Top-Line Data from the Dose-Escalation Cohorts of the Phase 2 Motor Study of Omaveloxolone in Patients With Mitochondrial Myopathies
finance.yahoo.com - March 2 at 10:26 AM |
| Reata Provides Program Update on Phase 2 Rare Renal Clinical Trials
finance.yahoo.com - February 28 at 10:41 AM |
| BidaskClub Lowers Reata Pharmaceuticals (RETA) to Strong Sell
www.americanbankingnews.com - February 24 at 10:22 PM |
| Reata Pharmaceuticals (RETA) Cut to "Sell" at Zacks Investment Research
www.americanbankingnews.com - February 17 at 1:48 PM |
| Reata Pharmaceuticals Inc (RETA) Expected to Post Quarterly Sales of $11.18 Million
www.americanbankingnews.com - February 17 at 5:46 AM |
| Reata Pharmaceuticals Inc (RETA) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 17 at 3:20 AM |
| Zacks: Analysts Anticipate Reata Pharmaceuticals Inc (RETA) Will Announce Earnings of -$0.58 Per Share
www.americanbankingnews.com - February 15 at 1:42 PM |
| Reata Pharma (RETA) Says Improvements in Kidney Function With Bardoxolone Methyl Maintained for Two Years in ... - StreetInsider.com
www.streetinsider.com - February 13 at 6:00 AM |
| Reata Announces Improvements in Kidney Function With Bardoxolone Methyl Maintained for Two Years in PAH Patients From LARIAT Trial
finance.yahoo.com - February 13 at 6:00 AM |
| Uniqure (QURE) and Reata Pharmaceuticals (RETA) Financial Survey
www.americanbankingnews.com - February 6 at 3:04 AM |
| $11.18 Million in Sales Expected for Reata Pharmaceuticals Inc (RETA) This Quarter
www.americanbankingnews.com - January 31 at 4:46 AM |
| Brokerages Expect Reata Pharmaceuticals Inc (RETA) Will Post Earnings of -$0.58 Per Share
www.americanbankingnews.com - January 29 at 1:12 PM |
Reata Pharmaceuticals (NASDAQ:RETA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Reata Pharmaceuticals (NASDAQ:RETA) Income Statement, Balance Sheet and Cash Flow Statement
Reata Pharmaceuticals (NASDAQ RETA) Stock Chart for Friday, April, 27, 2018
Loading chart…
